Press release
CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022
SOUTH SAN FRANCISCO, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated
About this update from Cytomx Therapeutics, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that preclinical data supporting the ongoing development of its conditionally activated cytokine program will be presented at the American Association for Cancer Research (AACR) Annual Meeting on April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. “Type I interferons, as monotherapy or in combination with PD-(L)1 blockade, are powerful antitumor agents, but the toxicity of these therapies, including interferon alpha, can limit their clinical use. We are working to address this limitation with our conditionally activated cytokine program,” said Marcia P. Belvin, Ph.D., senior vice president and head of research at CytomX Therapeutics. “At the upcoming AACR Annual Meeting, we will report encouraging preclinical data that support the development of our conditionally activated interferon alpha-2b therapeutic candidate as a promising addition to current immunotherapy regimens, potentially expanding benefit to patients with typically unresponsive tumors. This program represents the leading edge of a broad initiative at CytomX towards enhancing the therapeutic window of multiple cytokines.” Details for the poster presentation are as follows:Presentation Title: Probody-interferon-alpha 2b combines antitumor activity with improved tolerabilityAbstract Number: 2071Session Title: Immunomodulatory Agents and Interventions 1Session Date and Time: Monday, April 11, 2022, 1:30 - 5:00 pm CT About CytomX Therapeutics, Inc.CytomX is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. By pioneering a novel class of conditionally activated biologics, powered by its Probody® technology platform, CytomX’s goal is to transcend the limits of current cancer treatments by successfully leveraging therapeutic targets that were once thought to be inaccessible. CytomX’s robust and differentiated pipeline includes the wholly-owned praluzatamab ravtansine (CX-2009), an investigational conditionally activated antibody-drug conjugate (ADC) directed toward CD166, and CX-2029, an investigational conditionally activated ADC directed toward CD71 being developed in collaboration with AbbVie...